Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Skyrocketing Today

By George Budwell - Updated Mar 10, 2020 at 11:23AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Novavax lands a $4 million grant to develop its COVID-19 vaccine candidate.

What happened

Shares of the clinical-stage vaccine developer Novavax, Inc. (NVAX 1.55%) spiked by as much as 28% in pre-market trading Tuesday morning. The biotech's stock is responding to the news that the Coalition for Epidemic Preparedness (CEPI) awarded the company a $4 million grant to support the development of a COVID-19 vaccine.

Novavax is presently evaluating several COVID-19 vaccine candidates in pre-clinical studies, with the goal of advancing the most promising of the bunch into human trials by spring of this year. At the opening bell this morning, Novavax's shares were up by 17% in the wake of his news.  

A warning sign for coronavirus set against a blue sky.

Image source: Getty Images.

So what

Four million dollars isn't a whole lot in the context of developing a vaccine. But it is a step in the right direction. The big picture is that CEPI is clearly interested in Novavax's vaccine platform in the battle against the COVID-19 illness. More grant money, in turn, could be on the way as Novavax's COVID-19 efforts mature. 

Now what

Does this news change Novavax's fundamental outlook? In a word, no. Novavax and the entire field of players attempting to develop a COVID-19 vaccine are likely years away from realizing the fruits of their labor. By then, this deadly respiratory ailment will probably be old news. 

That doesn't mean Novavax's stock isn't worth considering here. The company is only a few weeks away from releasing the top-line results for its highly anticipated flu vaccine, NanoFlu. This vaccine candidate could transform the company into a commercial-stage entity and perhaps even a cash-flow-positive one at that. Still, the chance for another late-stage trial failure remains high. Investors shouldn't buy more than they can afford to lose when it comes to this promising, albeit risky, biotech stock

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$51.85 (1.55%) $0.79

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.